Daiichi Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Gastric Cancer at ASCO 2018 Gastrointestinal Cancers Symposium
Encouraging phase 1 results were shared at ASCO for DS-8201 (an antibody drug conjugate) treatment for HER2-positive gastric cancer.